Microshunt PRESERFLO™ for microinvasive glaucoma surgery
https://doi.org/10.53432/2078-4104-2025-24-2-61-72
Abstract
The current gold standard of glaucoma surgery is trabeculectomy, which allows sustained reduction of intraocular pressure (IOP). However, trabeculectomy is relatively traumatic and is associated with a risk of specific complications. As a result, a number of devices for microinvasive glaucoma surgery have been developed, designed to create a hypotensive effect comparable to trabeculectomy, coupled with minimal surgical trauma.
Microshunt PRESERFLO™ (Santen) is a polymer microshunt that facilitats the outflow of aqueous humor into the subconjunctival space with the formation of a filtering bleb. It is implanted through a subconjunctival approach, typical for trabeculectomy, however, due to the controlled aqueous outflow it minimizes the risk of complications typical for glaucoma interventions.
Long-term (up to 5 years) efficacy and safety of PRESERFLO™ microshunt implantation have been demonstrated in a number of studies, including those comparing PRESERFLO™ with other surgeries. Meta-analyses comparing PRESERFLO™ and trabeculectomy show comparable efficacy of the interventions with a lower risk of complications in PRESERFLO™. Studies comparing PRESERFLO™ with similarly designed microshunt XEN (Allergan, Plc, Ireland) show that PRESERFLO™ is either equally or more effective.
Supporting agencies: the authors received no specific funding for this work
About the Authors
V. P. Erichev
All-Russian public organization "Russian society of ophthalmologists-glaucoma specialists"
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Vice President
Moscow
K. B. Pershin
Ophthalmological center "Eximer"; Academy of Postgraduate Education of the Federal Medical-Biological Agency
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Medical Director; Professor at the Academic Department of Ophthalmology
3/1 Marksistskaya St., Moscow, 109147;
91 Volokolamskoe av., Moscow, 125371
A. V. Volzhanin
Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), researcher
11A Rossolimo St., Moscow, 119021
A. S. Makarova
Krasnov Research Institute of Eye Diseases
Russian Federation
Russian Federation
Cand. Sci. (Med.), researcher
11A Rossolimo St., Moscow, 119021
References
1. GBD 2019 Blindness and Vision Impairment Collaborators. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health 2021; 9(2):e144-e160. https://doi.org/10.1016/S2214-109X(20)30489-7.
2. Tham Y.C., Li X., Wong T.Y., Quigley H.A., Aung T., Cheng C.Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014; 121(11):2081-2090. https://doi.org/10.1016/j.ophtha.2014.05.013.
3. Neroev V.V., Mikhaylova L.A., Malishevskaya T.N., Petrov S.Yu., Filippova O.M. Glaucoma epidemiology in the Russian Federation. Russian Ophthalmological Journal 2024; 17(3):7-12. https://doi.org/10.21516/2072-0076-2024-17-3-7-12.
4. National glaucoma guidelines for practitioners. Ed. 4th, revised and enhanced. Egorov E.A., Erichev V.P., editors. Moscow, GEOTAR-Media Publ., 2019. 384 p.
5. European Glaucoma Society. Terminology and guidelines for glaucoma. Savona: PubliComm; 2020. 169 p.
6. Cairns J.E. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol 1968; 66(4):673-679.
7. Fedorov S.N., Kozlov V.I., Timoshkina N.T., Sharova A.B., Ereskin N.N., Kozlova E.E. Non-penetrating deep sclerectomy in open-angle glaucoma. Ophthalmosurgery 1989; (3-4):52-55.
8. Agrawal P., Bradshaw S.E. Systematic Literature Review of Clinical and Economic Outcomes of Micro-Invasive Glaucoma Surgery (MIGS) in Primary Open-Angle Glaucoma. Ophthalmol Ther 2018; 7(1): 49-73. https://doi.org/10.1007/s40123-018-0131-0.
9. Silber S., Colombo A., Banning A.P., Hauptmann K., et al. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxeleluting stents for de novo coronary artery lesions. Circulation 2009; 120(15):1498-1504. https://doi.org/10.1161/CIRCULATIONAHA.109.849877.
10. Strickler F., Richard R., McFadden S., Lindquist J., et al. In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. J Biomed Mater Res A 2010; 92(2):773-782. https://doi.org/10.1002/jbm.a.32418.
11. Kling J. The Lucrative Elution: Boston Scientific’s blockbuster medical device – and the novel way it was developed: MIT Technology Review; 2005. Available from: https://www.technologyreview.com/2005/10/01/101134/the-lucrative-elution/.
12. Pinchuk L., Riss I., Batlle J.F., Kato Y.P., et al. The development of a micro-shunt made from poly(styrene-block-isobutylene-blockstyrene) to treat glaucoma. J Biomed Mater Res B Appl Biomater 2017; 105(1):211-221. https://doi.org/10.1002/jbm.b.33525.
13. Acosta A.C., Espana E.M., Yamamoto H., Davis S., et al. A newly designed glaucoma drainage implant made of poly(styrene-b-isobutylene-b-styrene): biocompatibility and function in normal rabbit eyes. Arch Ophthalmol 2006; 124(12):1742-1749. https://doi.org/10.1001/archopht.124.12.1742.
14. Parel, J.M., Stoiber, J., Fernandez, V. Optical properties and biocompatibility of a novel polymer for intraocular implants: comparative study in the rabbit. (abstract). Ophthalmic Technologies XIV; 24–25 January 2004; San Jose 2004.
15. Arrieta E.A., Aly M., Parrish R., Dubovy S., et al. Clinicopathologic correlations of poly-(styrene-b-isobutylene-b-styrene) glaucoma drainage devices of different internal diameters in rabbits. Ophthalmic Surg Lasers Imaging 2011; 42(4):338-345. https://doi.org/10.3928/15428877-20110603-01.
16. Petrov SIu, Volzhanin AV. XEN-45 Gel Stent implant in glaucoma treatment. Russian Annals of Ophthalmology 2018;134(5):244-249. https://doi.org/10.17116/oftalma2018134051244.
17. Riss I., Batlle J., Pinchuk L., Kato Y.P., Weber B.A., Parel J.M. [One-year results on the safety and efficacy of the InnFocus MicroShunt depending on placement and concentration of mitomycin C]. J Fr Ophtalmol 2015; 38(9):855-860. https://doi.org/10.1016/j.jfo.2015.05.005.
18. Pinchuk L., Riss I., Batlle J.F., Kato Y.P., et al. The use of poly(styreneblock-isobutylene-block-styrene) as a microshunt to treat glaucoma. Regen Biomater 2016; 3(2):137-142. https://doi.org/10.1093/rb/rbw005.
19. Batlle J.F., Fantes F., Riss I., Pinchuk L., et al. Three-Year Follow-up of a Novel Aqueous Humor MicroShunt. J Glaucoma 2016; 25(2): e58-65. https://doi.org/10.1097/IJG.0000000000000368.
20. Batlle J.F., Corona A., Albuquerque R. Long-term Results of the PRESERFLO MicroShunt in Patients With Primary Open-angle Glaucoma From a Single-center Nonrandomized Study. J Glaucoma 2021; 30(3):281-286. https://doi.org/10.1097/IJG.0000000000001734.
21. Schlenker M.B., Durr G.M., Michaelov E., Ahmed I.I.K. Intermediate Outcomes of a Novel Standalone Ab Externo SIBS Microshunt With Mitomycin C. Am J Ophthalmol 2020; 215:141-153. https://doi.org/10.1016/j.ajo.2020.02.020.
22. Beckers H.J.M., Aptel F., Webers C.A.B., Bluwol E., et al. Safety and Effectiveness of the PRESERFLO(R) MicroShunt in Primary OpenAngle Glaucoma: Results from a 2-Year Multicenter Study. Ophthalmol Glaucoma 2022; 5(2):195-209. https://doi.org/10.1016/j.ogla.2021.07.008.
23. Pietris J., Casson R. One-Year Outcomes of Preserflo Microshunt for Primary Open Angle Glaucoma: A Systematic Review and MetaAnalysis. J Glaucoma 2024; 33(7):e27-e34. https://doi.org/10.1097/IJG.0000000000002419.
24. Pershin K.B., Pashinova N.F., Tsygankov A.Iu., Korneeva E.A., Solovyeva G.M. Preliminary results of PreserFlo® microshunt implantation in patients with primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma 2025; 24(1):24-31. https://doi.org/10.53432/2078-4104-2025-24-1-24-31.
25. Martínez-de-la-Casa J.M., Saenz-Francés F., Morales-Fernandez L., Perucho L., et al. Clinical outcomes of combined Preserflo Microshunt implantation and cataract surgery in open-angle glaucoma patients. Sci Rep 2021; 11(1):15600. https://doi.org/10.1038/s41598-021-95217-x.
26. Fili S., Kontopoulou K., Vastardis I., Perdikakis G., Bechrakis N., Kohlhaas M. PreserFlo MicroShunt Combined with Phacoemulsification versus PreserFlo MicroShunt as a Standalone Procedure in Patients with Medically Resistant Open-Angle Glaucoma. J Curr Ophthalmol 2022; 34(2):180-186. https://doi.org/10.4103/joco.joco_298_21.
27. Fea A.M., Laffi G.L., Martini E., Economou M.A., et al. Effectiveness of MicroShunt in Patients with Primary Open-Angle and Pseudoexfoliative Glaucoma: A Retrospective European Multicenter Study. Ophthalmol Glaucoma 2022; 5(2):210-218. https://doi.org/10.1016/j.ogla.2021.08.005.
28. Grobshäuser E., Cunha Vaz Martinho A., Gatzioufas Z., Hasler P., Maloca P., Gugleta K. Investigation of Endothelial Cell Density after PreserFlo Implantation Compared to Contralateral Eyes without PreserFlo Implantation — A Retrospective Analysis. Klin Monbl Augenheilkd 2025. https://doi.org/10.1055/a-2495-8580.
29. Gassel C.J., Wenzel D.A., Nasyrov E., Strasser T., Voykov B. Intermediate-term impact on corneal endothelial cells and efficacy of Preserflo MicroShunt implantation in patients with open-angle glaucoma — a prospective study over two years. Graefes Arch Clin Exp Ophthalmol 2024; 262(11):3661-3670. https://doi.org/10.1007/s00417-024-06508-8.
30. Anton Steindor F., Trigaux C., Holtmann C., Spaniol K., Geerling G., Borrelli M. Preserflo MicroShunt: Efficacy and Endothelial Cell Density. J Glaucoma 2023; 32(12):1018-1021. https://doi.org/10.1097/IJG.0000000000002325.
31. Bourauel L., Petrak M., Holz F.G., Mercieca K., Weber C. Short-Term Safety and Efficacy of PreserFlo Microshunt in Patients with Refractory Intraocular Pressure Elevation After Dexamethasone Implant Intravitreal Injection. J Clin Med 2025; 14(2). https://doi.org/10.3390/jcm14020507.
32. Rezkallah A., Loria O., Mathis T., Chacun S., Denis P., Kodjikian L. Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report. Case Rep Ophthalmol 2022; 13(3):1024-1029. https://doi.org/10.1159/000527672.
33. Nasyrov E., Seppelfricke C., Doycheva D., Gassel C.J., Merle D.A., Voykov B. Preserflo MicroShunt Implantation for Glaucoma Secondary to Viral and Juvenile Idiopathic Arthritis-Related Anterior Uveitis. Ocul Immunol Inflamm 2024:1-8. https://doi.org/10.1080/09273948.2024.2436101.
34. Triolo G., Wang J., Aguilar-Munoa S., Jayaram H., Barton K. Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes. Eye (Lond) 2023; 37(12):2535-2541. https://doi.org/10.1038/s41433-022-02368-w.
35. Ruparelia S., Darwich R., Eadie B.D. PreserFlo Microshunt for the management of intraocular pressure elevation in iridocorneal endothelial syndrome. Am J Ophthalmol Case Rep 2023; 32:101932. https://doi.org/10.1016/j.ajoc.2023.101932.
36. Martinez-de-la-Casa J.M., Saenz-Frances F., Morales Fernandez L., Garcia-Feijoo J. Posterior chamber implantation of a Preserflo Microshunt in a patient with a compromised endothelium. Arch Soc Esp Oftalmol (Engl Ed) 2022; 97(3):161-164. https://doi.org/10.1016/j.oftale.2022.02.002.
37. Dervos T., Gugleta K., Scholl H.P.N., Gatzioufas Z., Enz T.J. Single versus Double PreserFlo MicroShunt Implantation in Glaucoma Patients: A Retrospective Cohort Study. Ophthalmic Res 2023; 66(1):1362- 1375. https://doi.org/10.1159/000535276.
38. Majtanova N., Takacova A., Kurilova V., Hejsek L., Majtan J., Kolar P. One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge. Ophthalmol Ther 2025; 14(1):153-167. https://doi.org/10.1007/s40123-024-01074-y.
39. Strzalkowska A., Strzalkowski P., Hoffmann E.M., Pfeiffer N., Schuster A.K. Outcomes of Open Bleb Revision After PreserFlo MicroShunt Failure in Patients With Glaucoma. J Glaucoma 2023; 32(8):681-685. https://doi.org/10.1097/IJG.0000000000002246.
40. Governatori L., Oliverio L., Mermoud A., Scampoli A., et al. PreserFlo MicroShunt versus trabeculectomy: an updated meta-analysis and systematic review. Graefes Arch Clin Exp Ophthalmol 2024. https://doi.org/10.1007/s00417-024-06649-w.
41. Khan A., Khan A.U. Comparing the safety and efficacy of Preserflo Microshunt implantation and trabeculectomy for glaucoma: A systematic review and meta-analysis. Acta Ophthalmol 2024; 102(4): e443-e451. https://doi.org/10.1111/aos.16658.
42. Nakakura S., Oogi S., Terao E., Nagata Y., et al. Changes in Ocular Biometry Following PreserFlo MicroShunt Implantation and Trabeculectomy: A Prospective Observational Study. Cureus 2024; 16(3): e56188. https://doi.org/10.7759/cureus.56188.
43. Qidwai U., Jones L., Ratnarajan G. A comparison of iStent combined with phacoemulsification and endocyclophotocoagulation (ICE2) with the PreserFlo MicroShunt and XEN-45 implants. Ther Adv Ophthalmol 2022; 14:25158414221125697. https://doi.org/10.1177/25158414221125697.
44. Marolo P., Reibaldi M., Fallico M., Maugeri A., et al. Reintervention rate in glaucoma filtering surgery: A systematic review and meta-analysis. Eur J Ophthalmol 2022; 32(5):2515-2531. https://doi.org/10.1177/11206721221093828.
45. Scheres L.M.J., Kujovic-Aleksov S., Ramdas W.D., de Crom R., et al. XEN((R)) Gel Stent compared to PRESERFLO MicroShunt implantation for primary open-angle glaucoma: two-year results. Acta Ophthalmol 2021; 99(3):e433-e440. https://doi.org/10.1111/aos.14602.
46. Wagner F.M., Schuster A.K., Munder A., Muehl M., et al. Comparison of subconjunctival microinvasive glaucoma surgery and trabeculectomy. Acta Ophthalmol 2022; 100(5):e1120-e1126. https://doi.org/10.1111/aos.15042.
47. Nobl M., Freissinger S., Rudolph K., Vounotrypidis E., et al. Long-term Outcomes of PreserFlo MicroShunt versus XEN45 Gel Stent in OpenAngle Glaucoma. Klin Monbl Augenheilkd 2024; 241(7):805-812. https://doi.org/10.1055/a-2152-8455.
48. Lüke J.N., Dietlein T.S., Widder R.A., Roessler G.F., et al. Matched case-control comparison of surgical success after XEN45 Gel Stent and PRESERFLO MicroShunt implantation in a Caucasian population. Clin Exp Ophthalmol 2024; 52(7):732-739. https://doi.org/10.1111/ceo.14407.
49. María Martínez-de-la-Casa J.M., Pascual-Santiago A., Morales-Fernandez L., Saez-Frances F., et al. Xen 63 versus Preserflo MicroShunt implant in patients with primary open-angle glaucoma. Sci Rep 2025; 15(1):1634. https://doi.org/10.1038/s41598-024-81616-3.
50. Gambini G., Carla M.M., Giannuzzi F., Boselli F., et al. Anterior Segment-Optical Coherence Tomography Bleb Morphology Comparison in Minimally Invasive Glaucoma Surgery: XEN Gel Stent vs. PreserFlo MicroShunt. Diagnostics (Basel) 2022; 12(5). https://doi.org/10.3390/diagnostics12051250.
51. Hasan S.M., Theilig T., Papadimitriou M., Meller D. A Comparative Analysis of Morphology and Dimensions of Functional Blebs following PRESERFLO-Microshunt and XEN-Gel-Stent, a Study Using Anterior Segment OCT. Diagnostics (Basel) 2023; 13(14). https://doi.org/10.3390/diagnostics13142318.
52. Neubauer J., Suesskind D., Gassel C.J., Nasyrov E., Voykov B. Histopathological findings of failed blebs after microinvasive bleb surgery with the XEN Gel Stent and Preserflo MicroShunt. Graefes Arch Clin Exp Ophthalmol 2024; 262(9):2977-2984. https://doi.org/10.1007/s00417-024-06479-w.
53. Theilig T., Papadimitriou M., Albaba G., Meller D., Hasan S.M. Results of open bleb revision as management of primary bleb failure following XEN 45 gel stent and Preserflo Microshunt. Graefes Arch Clin Exp Ophthalmol 2023; 261(11):3249-3255. https://doi.org/10.1007/s00417-023-06152-8.
54. Steiner S., Resch H., Kiss B., Vass C. PRESERFLO Microshunt: 1-Year Results of a 25-Gauge vs. 27-Gauge Needle Tract. J Clin Med 2024; 13(7). https://doi.org/10.3390/jcm13071979.
55. Fea A.M., Ghilardi A., Bovone D., Reibaldi M., Rossi A., Craven E.R. A New and Easier Approach to Preserflo MicroShunt Implantation. Clin Ophthalmol 2022; 16:1281-1288. https://doi.org/10.2147/OPTH.S307835.
56. Miura Y., Fukuda K., Yamashiro K. Comparison of outcomes with and without intrastent placement during PMS surgery. Sci Rep 2025; 15(1):2981. https://doi.org/10.1038/s41598-025-87259-2.
57. Verma-Fuehring R., Dakroub M., Bamousa A., Kann G., Hillenkamp J., Kampik D. The use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony. Graefes Arch Clin Exp Ophthalmol 2024; 262(12):3925-3932. https://doi.org/10.1007/s00417-024-06567-x.
58. Miura Y., Fukuda K., Yamashiro K. Ab Interno Intraluminal Stent Insertion for Prolonged Hypotony After PreserFlo MicroShunt Implantation. Cureus 2024; 16(5):e60221. https://doi.org/10.7759/cureus.60221.
59. Lupardi E., Laffi G.L., Moramarco A., Barboni P., Fontana L. Systematic Preserflo MicroShunt Intraluminal Stenting for Hypotony Prevention in Highly Myopic Patients: A Comparative Study. J Clin Med 2023; 12(4):1677. https://doi.org/10.3390/jcm12041677.
60. Schneider S., Kallab M., Murauer O., Reisinger A.S., et al. Bleb vessel density as a predictive factor for surgical revisions after Preserflo Microshunt implantation. Acta Ophthalmol 2024; 102(5):e797-e804. https://doi.org/10.1111/aos.16642.
61. Cagini C., Boni N., Bonifazi T., Fruttini D., Della Lena F. Efficacy and Safety of PreserFlo MicroShunt Implantation and Its Effects on Intraocular Inflammation through Laser Flare Photometry. J Ophthalmol 2024; 2024:2447721. https://doi.org/10.1155/2024/2447721.
62. Rojo-Arnao M., Martinez-de-la-Casa J.M., Albis-Donado O., YanezCastro G., et al. Preserflo TM MicroShunt implantation combined with Ologen TM in primary and secondary glaucoma patients in a clinical setting. Indian J Ophthalmol 2024; 72(3):417-426. https://doi.org/10.4103/IJO.IJO_1502_23.
63. Nakakura S., Nagata Y., Fujisawa Y., Kiuchi Y. Scleral bridging technique for preventing PreserFlo microshunt exposure: A case report. Medicine (Baltimore) 2024; 103(27):e38847. https://doi.org/10.1097/MD.0000000000038847.
64. Morales-Fernández L., Pérez-García P., Martínez-de-la-Casa J.M., Sáenz-Francés F., et al. Intraoperative OCT to check the correct postimplant position of Preserflo(TM). Eur J Ophthalmol 2024: 11206721241272169. https://doi.org/10.1177/11206721241272169.
Review
For citations:
Erichev V.P., Pershin K.B., Volzhanin A.V., Makarova A.S. Microshunt PRESERFLO™ for microinvasive glaucoma surgery. National Journal glaucoma. 2025;24(2):61-72. (In Russ.) https://doi.org/10.53432/2078-4104-2025-24-2-61-72
Views:
97
Email this article 